A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6).
Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL; STRIDE-6 Study Group.
Clin Infect Dis. 2024 Dec 17;79(6):1366-1374. doi: 10.1093/cid/ciae383.
Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques.
McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ.
Infect Immun. 1998 Aug;66(8):3705-10. doi: 10.1128/IAI.66.8.3705-3710.1998.
How to use antistreptolysin O titre.
Sen ES, Ramanan AV.
Arch Dis Child Educ Pract Ed. 2014 Dec;99(6):231-8. doi: 10.1136/archdischild-2013-304884. Epub 2014 Jan 30.
Antistreptolysin O; a study of this antibody in health and in hemolytic streptococcus respiratory disease in man.
RANTZ LA, RANDALL E, RANTZ HH.
Am J Med. 1948 Jul;5(1):3-23. doi: 10.1016/0002-9343(48)90003-5.
Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection.
Aikawa C, Kawashima K, Fukuzaki C, Nakakido M, Murase K, Nozawa T, Tsumoto K, Nakagawa I.
Biochem Biophys Res Commun. 2021 Aug 20;566:177-183. doi: 10.1016/j.bbrc.2021.06.021. Epub 2021 Jun 12.
An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome.
Matsumura T, Nishiyama A, Aiko M, Ainai A, Ikebe T, Chiba J, Ato M, Takahashi Y.
BMC Res Notes. 2020 Sep 5;13(1):419. doi: 10.1186/s13104-020-05264-2.
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Gallagher KE, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, Mwalekwa L, Ragab S, Twi-Yeboah L, Berkley JA, Hamaluba M, Karani A, Shangala J, Otiende M, Gardiner E, Mugo D, Smith PG, Tabu C, Were F, Goldblatt D, Scott JAG.
N Engl J Med. 2024 Nov 28;391(21):2003-2013. doi: 10.1056/NEJMoa2314620. Epub 2024 Sep 26.
Post-streptococcal uveitis.
Besada E, Schatz S, Saremi SS.
Optometry. 2000 Apr;71(4):233-8.
An mRNA vaccine encoding five conserved Group A Streptococcus antigens.
Harbison-Price N, Sebina I, Bolton RA, Finn M, Cork AJ, Courtney IG, Hancock S, Pelingon R, Richter J, Ericsson O, Green S, Cuellar C, Davis L, Pullinger B, Na J, Elangovan G, De Oliveira DMP, Curren BF, Bickham N, Aguirre M, Dold C, Brouwer S, Plante O, Belz GT, Walker MJ.
Nat Commun. 2025 Jul 1;16(1):5439. doi: 10.1038/s41467-025-60580-0.
Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence.
Chiarot E, Faralla C, Chiappini N, Tuscano G, Falugi F, Gambellini G, Taddei A, Capo S, Cartocci E, Veggi D, Corrado A, Mangiavacchi S, Tavarini S, Scarselli M, Janulczyk R, Grandi G, Margarit I, Bensi G.
mBio. 2013 Jan 8;4(1):e00387-12. doi: 10.1128/mBio.00387-12.
